The advanced lung cancer inflammation index is a novel independent prognosticator in colorectal cancer patients after curative resection

Taichi Horino ◽  
Ryuma Tokunaga ◽  
Yuji Miyamoto ◽  
Yukiharu Hiyoshi ◽  
Takahiko Akiyama ◽  
2009 ◽  
Vol 100 (8) ◽  
pp. 736-743 ◽  
Hsiang-Lin Tsai ◽  
Koung-Shing Chu ◽  
Yu-Ho Huang ◽  
Yu-Chung Su ◽  
Jeng-Yih Wu ◽  

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4696-4696
Scott Davi d Ramsey ◽  
Jeannine S McCune ◽  
David K Blough ◽  
Lauren C Clarke ◽  
Cara L McDermott ◽  

Abstract Chemotherapy regimens, patient factors, and the use of colony stimulating factor (CSF) influence cancer patients’ risk for febrile neutropenia (FN) when they receive myelosuppressive chemotherapy. The incidence of FN and patient factors influencing that risk are relatively unknown in community settings. Using claims from Medicare, Medicaid and two private health insurance plan enrollees linked to the Puget Sound SEER registry, we examined the incidence of FN among breast, lung and colorectal cancer patients diagnosed 2002–05 who received adjuvant chemotherapy. We used logistic regression models to determine factors influencing the risk for FN within the first chemotherapy cycle, controlling for cancer stage, age, sex, race, comorbidities, chemotherapy-regimen related FN risk (as designated by the National Comprehensive Cancer Network), CSF use, health insurance type, and surgery or radiation ≤30 days from administration of first chemotherapy. Over the time horizon, 1096 breast, 1142 lung, and 755 colorectal cancer patients received chemotherapy. The incidence of any FN in the first chemotherapy cycle was (counts per 100 recipients by high, intermediate, and low-risk myelosuppressive chemotherapy according to NCCN categories respectively) 7.36, 10.0, 4.70 for breast cancer, 17.12, 14.15, 12.22 for lung cancer, and 25.0, 8.96, 6.37 for colorectal cancer. Significant predictors (p<0.05) of any FN were: breast cancer—radiation ≤ 30 days from first chemotherapy administration (OR 2.90, 95% CI 1.21–6.94), other non-black race vs. white race (OR 2.82, 95% CI 1.29–6.17), or Medicaid insurance (OR 2.31, 95% CI 1.10–4.89); lung cancer—radiation ≤ 30 days from first chemotherapy administration (OR 1.63, 95% CI 1.01–2.61), surgery ≤ 30 days from first chemotherapy administration (OR 2.08, 95% CI 1.02–4.25), Medicaid insurance (OR 2.29, 95% CI 1.08–4.84), or a Charlson comorbidity score ≥ 2 (OR 2.56, 95% CI 1.11–5.91); colorectal cancer—female gender (OR 1.86, 95% CI 1.02–3.41) or high myelosuppressive risk chemotherapy regimen (OR 7.66, 95% CI 2.95–19.89). In this analysis, predictors of FN varied between cancers. Limitations of this analysis include lack of information about chemotherapy and CSF doses, as this is not captured in the SEER registry or claims data. These results indicate that several factors may interact to influence a patient’s likelihood of developing FN in the first cycle of adjuvant chemotherapy.

2019 ◽  
Vol 17 (1) ◽  
Xin Hua ◽  
Jing Chen ◽  
Ying Wu ◽  
Jun Sha ◽  
Shuhua Han ◽  

Abstract Background Inflammation plays a critical role in the development and progression of cancers. The advanced lung cancer inflammation index (ALI) is thought to be able to reflect systemic inflammation better than current biomarkers. However, the prognostic significance of the ALI in various types of cancer remains unclear. Our meta-analysis aimed to comprehensively investigate the relationship between the ALI and oncologic outcomes to help physicians better assess the prognosis of cancer patients. Methods The PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases were searched for relevant studies. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated and pooled from the included studies. Furthermore, a sensitivity analysis was performed to evaluate the reliability of the articles. Finally, Begg’s test, Egger’s test, and the funnel plot were applied to assess the significance of publication bias. Results In total, 1736 patients from nine studies were included in our meta-analysis. The median cutoff value for the ALI was 23.2 (range, 15.5–37.66) in the analyzed studies. The meta-analysis showed that there was a statistically significant relationship between a low ALI and worse overall survival (OS) in various types of cancer (HR = 1.70, 95% CI = 1.41–1.99, P < 0.001). Moreover, results from subgroup meta-analysis showed that the ALI had a significant prognostic value in non-small cell lung cancer, small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and diffuse large B cell lymphoma (P < 0.05 for all). Conclusions These results showed that a low ALI was associated with poor OS in various types of cancer, and the ALI could act as an effective prognostic biomarker in cancer patients.

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e10100
Hailun Xie ◽  
Shizhen Huang ◽  
Guanghui Yuan ◽  
Jiaan Kuang ◽  
Ling Yan ◽  

Background and Purpose Several studies have proposed that the advanced lung cancer inflammation index (ALI), a new inflammation-related index, can be used for the prognosis assessment of various malignancies. However, few studies have reported its prognostic value in colorectal cancer (CRC). Therefore, this study explored the relationship between ALI and outcomes in CRC patients. Methods A total of 662 CRC patients who underwent surgery between 2012 and 2014 were included. The ALI was defined as: body mass index × serum albumin/neutrophil to lymphocyte ratio. The X-tile program identified the optimal cut-off value of ALI. Logistic regression analyses determined factors affecting postoperative complications. The Kaplan–Meier method and Cox proportional hazards analyses evaluated potential prognostic factors. Results The optimal cut-off of ALI in males and females were 31.6 and 24.4, respectively. Low-ALI was an independent risk factor for postoperative complications in CRC patients (odds ratio: 1.933, 95% CI [1.283–2.911], p = 0.002). Low-ALI groups also had significantly lower progression-free survival (PFS) and overall survival (OS), when compared with the high-ALI group, especially at advance tumor stages. Using multivariate analysis, ALI was determined as an independent prognostic factor for PFS (hazard ratio: 1.372, 95% CI [1.060–1.777], p = 0.016) and OS (hazard ratio: 1.453, 95% confidence interval: 1.113–1.898, p = 0.006). Conclusion ALI is an independent predictor of short and long-term outcomes in CRC patients, especially at advance tumor stages. The ALI-based nomograms can provide accurate and individualized prediction of postoperative complication risk and survival for CRC patients.

Pham Thi Bich ◽  
Nguyen Thi Van ◽  
Ta Van To ◽  
Trinh Hong Thai

Some mutations of mt-DNA which encode tRNA (mt-tRNA) were previously reported  to be associated with clinical manifestations of neuromuscular disorders syndrome. In addition, alterations of the mitochondrial genome have been suggested to contribute to mitochondrial dysfunction and tumorigenesis. Alterations in some mt-tRNA genes have also been identified in breast cancer, lung cancer and colorectal cancer. However, so far, we have not found any report on mt-tRNA gene alteration in the Vietnamese colorectal cancer patients. So that, in this study, we analyzed the alterations of some mt-tRNA genes in a group of  Vietnamese colorectal cancer patients and predicted influence of the alterations to secondary structure of tRNA based on bioinformatic tools. PCR-RFLP and DNA sequencing methods were used to screening alterations, secondary structure of tRNA was predicted in silico by using a tool of the  Vienna RNA Websuite. Results: both A12309G and A12310G of tRNALeu were identified together in two out of 98 patients, and both T12150G and C12154G of tRNAHis were indentified in one  out of 19 patients. All of these alterations were heteroplasmic and have not been reported in cancer patients. In particular, the C12154G  alteration in the DHR loop led to change of secondary structure of  tRNAHis and may affect to function of this tRNA molecule. Keywords mt-tRNA, Vietnamese colorectal cancer, PCR-RFLP, DNA sequencing References [1] (30/11/2017).[2] M. Brandon, P. Baldi, D.C Wallace, Mitochodrial mutations in cancer, Oncogen 25(34) (2006) 4647.[3] G. Li, YX. Duan, XB. Zhang, F Wu, Mitochondrial RNA mutations may be infrequent in hepatocellular carcinoma patients, Genet Mol Res15(2) (2016) doi: 10.4238/gmr.15027665.[4] F. Mohammed, AR. Rezaee, E. Mosaieby, M. Houshmand, Mitochondrial A12308G alteration in RNA Leu (CUN)) in colorectal cancer samples, Diagn Pathol (2015) doi: 10.1186/s13000-015-0337-6.[5] S. Datta, M. Majumder, NK. Biswas, N. Sikdar, B. Roy, Increased risk of oral cancer in relation to common Indian mitochondrial polymorphisms and Autosomal GSTP1 locus, Cancer, 110 (2007) 1999.[6] L .Wang , ZJ. Chen , YK. Zhang , HB. Le, The role of mitochondrial RNA mutations in lung cancer, Int J Clin Exp Med 8(8) (2015) 13341.[7] AR. Gruber, R. Lorenz, SH. Bernhart, R. Neubock, IL Hofacker The Vienna ARN Websuite, Nucleic Acids Res 36 (2008) 70.[8] (11/2017).[9] Y. Goto, I Nonaka, S Horai, A mutation in the RNALeu (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies, Nature 348(6302 (1990) 651[10] (11/2017).[11] A. Lorenc, J. Bryk Golik P, Homoplasmic MELAS A3243G mtDNA mutation in a colon cancer sample, Mitochondrion 3(2) (2003) 119.[12] EL. Blakely, J.W Yarham , C.L. Alston , K Craig , J. Poulton , C. Brierley , SM. Park , A. Dean , JH. Xuereb , KN. Anderson , A. Compston , C. Allen , S. Sharif , P. Enevoldson , M. Wilson , SR. Hammans , DM. Turnbull , R. McFarland , RW.Taylor , Pathogenic mitochondrial tRNA point mutations: nine novel mutations affirm their importance as a cause of mitochondrial disease, Hum Mutat 34(9) (2013) 1260.[13] S. DiMauro, Mitochondrial ADN medicine, Biosci Rep 27(3) (2007) 5.[14] DC. Wallace, D. Chalkia, Mitochondrial ADN genetics and the heteroplasmy conundrum in evolution and disease”, Cold Spring Harb Perspect Biol 5(11) (2013), doi:10.1101/cshperspect. a021220  

Sign in / Sign up

Export Citation Format

Share Document